Neuropathix, Inc.
NPTX · OTC
3/31/2022 | 12/31/2021 | 9/30/2021 | 6/30/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 37.3% | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 100% | 100% | – | – |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $0 | $1 | $0 | $1 |
| SG&A Expenses | $0 | $1 | $0 | $1 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$0 | $0 | -$0 | $0 |
| Operating Expenses | $0 | $1 | $1 | $1 |
| Operating Income | $1 | -$1 | -$1 | -$1 |
| % Margin | 268.5% | -439.7% | – | – |
| Other Income/Exp. Net | -$1 | -$0 | -$0 | -$0 |
| Pre-Tax Income | -$2 | -$1 | -$1 | -$1 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$2 | -$1 | -$1 | -$1 |
| % Margin | -913.6% | -499.6% | – | – |
| EPS | -0.021 | -0.009 | -0.008 | -0.009 |
| % Growth | -139.5% | -7.5% | 5.9% | – |
| EPS Diluted | -0.021 | -0.009 | -0.008 | -0.009 |
| Weighted Avg Shares Out | 92 | 88 | 90 | 88 |
| Weighted Avg Shares Out Dil | 92 | 88 | 90 | 88 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | $1 | -$1 | -$0 | -$1 |
| % Margin | 284% | -400.7% | – | – |